TrialThe Lancet. Oncology2025

Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study.

Ramaprasad Srinivasan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.